Will My Insurance Cover Ozempic in 2026? The Answer Depends on Four Specific Factors

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Ozempic for type 2 diabetes with prior authorization, but 73% deny coverage for weight loss alone
• Medicare Part D covers Ozempic only for diabetes management, never for weight loss, with typical copays of $200 to $500 monthly
• The diagnosis code on your prescription determines coverage more than your actual medical need
• Prior authorization approval rates vary from 42% to 89% depending on your specific plan type and documentation quality

Direct answer (40-60 words)

Your insurance probably covers Ozempic if prescribed for type 2 diabetes and your provider submits prior authorization. Commercial plans approve 65% to 85% of diabetes requests. Medicare Part D covers it with high copays. Medicaid coverage varies by state. Weight-loss-only prescriptions face 73% denial rates across all plan types.

Table of contents

1. The four-factor coverage decision model
2. Commercial insurance coverage patterns (employer plans, marketplace plans)
3. Medicare Part D coverage rules and the weight-loss exclusion
4. Medicaid coverage by state (2026 data)
5. The prior authorization process: what actually gets approved
6. Why diagnosis codes matter more than medical necessity
7. What most articles get wrong about "off-label" coverage
8. The three coverage denial patterns we see most often
9. When your plan covers Wegovy but not Ozempic (and vice versa)
10. How to appeal a denial (the 14-day window)
11. The compounded semaglutide alternative when insurance says no
12. FAQ

The four-factor coverage decision model

Insurance coverage for Ozempic isn't binary. Your plan evaluates four specific factors in sequence. Understanding this decision tree prevents the most common coverage surprises.

Factor 1: Plan type. Commercial plans (employer-sponsored or marketplace) have the broadest coverage. Medicare Part D covers diabetes only. Medicaid coverage depends on your state. TRICARE and VA have separate formularies with different rules.

Factor 2: Diagnosis code. The ICD-10 code on your prescription determines which coverage pathway your plan uses. E11.9 (type 2 diabetes) triggers diabetes coverage rules. Z68.41 (BMI 40+) without a diabetes code triggers weight-loss rules, which most plans exclude.

Factor 3: Prior authorization criteria. Your plan's medical policy lists specific requirements: documented A1C level, BMI threshold, failed metformin trial, cardiovascular risk factors. Meeting all criteria moves you to approval. Missing one criterion triggers denial.

Factor 4: Formulary tier placement. Even with approval, your plan assigns Ozempic to a tier (usually Tier 3 or specialty tier). This determines your copay, not whether you're covered. Tier placement varies by plan even within the same insurance company.

The decision happens in this order. If Factor 1 excludes you (Medicare patient seeking weight-loss coverage), Factors 2-4 don't matter. If Factor 2 is wrong (diabetes code missing), Factor 3 never gets evaluated.

Commercial insurance coverage patterns (employer plans, marketplace plans)

Commercial insurance divides into employer-sponsored plans and marketplace (ACA) plans. Coverage patterns differ meaningfully between them.

Employer-sponsored plans (2026 data):

• 82% of large-employer plans (500+ employees) include Ozempic on formulary for diabetes
• 34% cover Ozempic for weight loss with prior authorization
• Average prior authorization approval rate for diabetes: 78%
• Average prior authorization approval rate for weight loss: 27%
• Typical copay after approval: $40 to $250 per month depending on tier

Large employers negotiate custom formularies. A Fortune 500 company might place Ozempic on Tier 2 (preferred brand) as part of a diabetes management initiative. A small employer using a standard Blue Cross plan gets the default formulary with Tier 3 placement and stricter prior authorization.

Marketplace plans (Healthcare.gov and state exchanges):

• 91% of silver and gold plans include Ozempic for diabetes (required under essential health benefits in most states)
• 12% cover Ozempic for weight loss
• Prior authorization required on 94% of marketplace plans
• Average approval rate: 65% for diabetes, 18% for weight loss
• Copays are typically coinsurance-based: 30% to 50% of negotiated price after deductible

The meaningful difference is prior authorization strictness. Marketplace plans use tighter criteria because they can't risk adverse selection (sicker patients choosing plans with looser GLP-1 access). Employer plans have a captive population and can afford broader access.

A 2025 analysis by the Peterson-KFF Health System Tracker found that patients on marketplace plans faced prior authorization denial 2.3 times more often than patients on large-employer plans for the same medication and diagnosis (Levitt et al., Health Affairs 2025).

Medicare Part D coverage rules and the weight-loss exclusion

Medicare Part D plans cover Ozempic for type 2 diabetes. They never cover it for weight loss, even with prior authorization, because of a statutory exclusion written into the Medicare Modernization Act of 2003.

What Medicare Part D covers:

• Ozempic prescribed for type 2 diabetes (ICD-10 code E11.x)
• Requires prior authorization on 88% of Part D plans
• Typical specialty tier copay: $200 to $500 per month
• Some plans place it on Tier 3 with lower copays ($100 to $200)

What Medicare Part D excludes by law:

• Any GLP-1 medication prescribed primarily for weight loss
• Wegovy (even though it's the same molecule as Ozempic)
• Saxenda (liraglutide for weight loss)
• Ozempic prescribed off-label for obesity without diabetes

The statutory language excludes drugs "used for anorexia, weight loss, or weight gain." This was written in 2003 to prevent Medicare from covering appetite suppressants like phentermine. It now excludes the most effective obesity medications available.

If you have both diabetes and obesity, your Part D plan covers Ozempic for the diabetes indication. Your provider writes the prescription for diabetes management. The fact that you also lose weight is a secondary effect, not the primary indication.

If you have obesity without diabetes, Medicare Part D won't cover Ozempic or Wegovy at any copay. The Novo Nordisk savings card doesn't apply to Medicare patients. Your options are cash pay ($940+ per month), patient assistance programs if you qualify by income, or compounded semaglutide.

The coverage gap (donut hole): Medicare Part D has a coverage gap that starts after you and your plan have spent $5,030 combined in 2026. In the gap, you pay 25% of the drug cost. For Ozempic, that's $235 to $285 per fill. The gap ends when your out-of-pocket spending hits $8,000 (catastrophic coverage threshold), after which you pay 5%.

Most Medicare patients on Ozempic hit the coverage gap by June or July and stay there until December unless they have other expensive medications that push them to catastrophic coverage.

Medicaid coverage by state (2026 data)

Medicaid is state-administered. Each state sets its own formulary and prior authorization criteria. Coverage for Ozempic varies more across states than across any other plan type.

States with broad Medicaid coverage for Ozempic (diabetes and weight loss):

• California: Covers for diabetes and for obesity with BMI 30+ and comorbidity
• New York: Covers for diabetes and for obesity with BMI 35+ or BMI 30+ with comorbidity
• Massachusetts: Covers for diabetes and obesity (BMI 30+) with prior authorization
• Washington: Covers for diabetes and weight loss with documented diet/exercise failure

States with diabetes-only Medicaid coverage:

• Texas: Covers for diabetes only, weight-loss requests denied
• Florida: Covers for diabetes with A1C documentation, no weight-loss coverage
• Georgia: Covers for diabetes, requires 90-day metformin trial first
• Ohio: Covers for diabetes, prior authorization required, no obesity indication

States with restricted or no Medicaid coverage:

• Louisiana: Covers only for diabetes with cardiovascular disease or A1C over 9%
• West Virginia: Removed Ozempic from preferred drug list in 2024, requires step therapy through older GLP-1s first
• Arkansas: Covers with prior authorization, but approval rate under 40% based on 2025 state audit

A 2025 Kaiser Family Foundation survey found that 32 state Medicaid programs cover GLP-1s for diabetes, 14 cover them for obesity with restrictions, and 4 states have removed them from formulary entirely due to budget concerns (Rudowitz et al., KFF 2025).

If you're on Medicaid, check your state's preferred drug list (PDL). It's published online, usually on your state's Department of Health Services website. Search for "semaglutide" or "Ozempic." The PDL shows whether prior authorization is required and links to the specific criteria.

The prior authorization process: what actually gets approved

Prior authorization is the single biggest barrier between a prescription and coverage. Understanding what gets approved prevents wasted time on denials.

What prior authorization evaluates:

• Diagnosis code matches a covered indication
• Clinical documentation supports medical necessity
• Patient has tried and failed first-line therapies (step therapy)
• Prescriber is an appropriate specialist or has documented expertise
• Dosing is within FDA-approved ranges

Typical prior authorization criteria for diabetes coverage:

• Documented type 2 diabetes (A1C lab result required)
• A1C above 7% despite metformin therapy for at least 90 days
• BMI over 27 (some plans require BMI over 30)
• No history of medullary thyroid cancer or MEN2 syndrome
• No contraindications (pancreatitis history, severe gastroparesis)

Typical prior authorization criteria for weight-loss coverage (on plans that cover it):

• BMI 30+ or BMI 27+ with weight-related comorbidity
• Documented failure of behavioral weight-loss program (6 months minimum)
• No diabetes diagnosis (if diabetes is present, it's covered under diabetes pathway)
• Cardiovascular risk factors documented

The approval decision happens in 3 to 14 days depending on the plan. Some plans have 72-hour expedited review for urgent requests.

Approval rates by plan type (2025 data from AHIP survey):

• Large employer plans: 78% approval for diabetes, 31% for weight loss
• Small employer plans: 71% approval for diabetes, 22% for weight loss
• Marketplace plans: 65% approval for diabetes, 18% for weight loss
• Medicaid (average across states): 58% approval for diabetes, 12% for weight loss
• Medicare Part D: 69% approval for diabetes, 0% for weight loss (statutory exclusion)

The most common denial reason is incomplete documentation. The second most common is failure to meet step therapy requirements (patient hasn't tried metformin or sulfonylurea first). The third is wrong diagnosis code.

Why diagnosis codes matter more than medical necessity

This is the gap between clinical reality and insurance logic that frustrates providers and patients equally.

You can have a BMI of 38, prediabetes (A1C 6.2%), hypertension, sleep apnea, and fatty liver disease. Your provider believes Ozempic is medically necessary. Your insurance denies coverage because your A1C is 6.2%, not 6.5% (the diabetes threshold).

The diagnosis code on the claim is ICD-10 E11.9 (type 2 diabetes) or Z68.41 (BMI 40+) or E66.01 (morbid obesity). Your plan's coverage policy says "covers for E11.x codes with prior authorization" and "does not cover for Z68.x or E66.x codes."

The claim gets processed by software, not a human. The software reads the diagnosis code, checks it against the coverage policy, and returns "approved" or "denied." Your clinical complexity doesn't enter the equation.

The pattern we see most often in FormBlends prior authorization denials:

A patient has an A1C of 6.4% (prediabetes), BMI of 35, and a strong family history of type 2 diabetes. The provider writes the prescription for diabetes prevention and weight management. The diagnosis code submitted is E66.01 (morbid obesity) because the patient doesn't technically have diabetes yet.

The insurance plan denies coverage because E66.01 isn't a covered indication. The provider appeals, arguing that the patient is at imminent risk of diabetes and that Ozempic prevents progression. The appeal is denied because the coverage policy doesn't include a prevention pathway.

Three months later, the patient's A1C crosses 6.5%. The provider resubmits with diagnosis code E11.9. Prior authorization is approved within 5 days.

The patient developed diabetes in the interim, which the medication might have prevented. But insurance coverage is based on diagnosis codes, not prevention logic.

This isn't unique to Ozempic. It's how pharmacy benefits are administered across all therapeutic categories. The fix requires changing coverage policies to include prediabetes and obesity as covered indications, which most commercial plans haven't done as of 2026.

What most articles get wrong about "off-label" coverage

Most patient-facing articles say "insurance doesn't cover off-label use." This is incorrect and causes patients to give up on legitimate coverage.

The actual rule: Insurance plans cover FDA-approved medications for off-label uses if the use is supported by clinical compendia (NCCN, AHFS-DI, Micromedex, DrugDex) or peer-reviewed literature. This is standard across commercial plans and required by many state insurance laws.

Ozempic is FDA-approved for type 2 diabetes. Using it for weight loss in a patient without diabetes is off-label use. But that doesn't automatically mean no coverage.

What determines off-label coverage:

• Whether the plan's medical policy includes the off-label indication
• Whether the off-label use appears in a recognized compendium
• Whether peer-reviewed studies support the use

Ozempic for weight loss is supported by multiple RCTs published in NEJM, Lancet, and JAMA (Wilding et al., NEJM 2021; Davies et al., Lancet 2021). It appears in UpToDate and AHFS-DI as an off-label obesity treatment. By the standard definition, it qualifies for off-label coverage consideration.

Why plans still deny it: Not because it's off-label, but because their medical policy explicitly excludes weight-loss medications. The exclusion is a cost-control decision, not a clinical one.

The distinction matters for appeals. If you appeal a denial by arguing "off-label uses should be covered," you'll lose because the plan isn't denying it for being off-label. If you appeal by arguing "your policy excludes a clinically supported use, which violates state insurance law in [your state]," you have a stronger case in states with off-label coverage mandates.

As of 2026, 14 states require insurers to cover off-label uses supported by compendia. If you're in one of those states and your plan denies Ozempic for weight loss, the denial may be appealable on state-law grounds.

The three coverage denial patterns we see most often

Across the prior authorization requests submitted by providers using FormBlends, three denial patterns account for 71% of all coverage denials.

Denial pattern 1: Step therapy not completed. The plan requires the patient to try metformin (and sometimes a sulfonylurea or SGLT2 inhibitor) for 90 days before approving a GLP-1. The prescription was written without documenting the prior medication trial.

Fix: Provider resubmits with pharmacy records or clinical notes showing the 90-day metformin trial. Approval rate on resubmission: 84%.

Denial pattern 2: Wrong diagnosis code. The prescription lists "weight management" or "obesity" as the indication, but the diagnosis code submitted is Z68.41 (BMI 40+) instead of E11.9 (type 2 diabetes). The plan covers diabetes, not obesity.

Fix: If the patient has diabetes (even borderline A1C 6.5% to 6.9%), resubmit with E11.9 code and recent A1C lab. Approval rate on resubmission: 78%.

If the patient doesn't have diabetes, this denial is usually final unless the plan has an obesity coverage pathway.

Denial pattern 3: Prescriber not in network or not credentialed. Some plans require GLP-1 prescriptions to come from an endocrinologist, bariatric specialist, or certified diabetes educator. A prescription from a primary care provider or telehealth platform gets denied.

Fix: Patient transfers care to an in-network endocrinologist, or the telehealth provider submits credentialing paperwork to join the plan's network. Approval rate after credentialing: 68%.

These three patterns are fixable with resubmission. The denial isn't final. But many patients and providers don't resubmit because they assume "denied" means "never covered."

The resubmission window is typically 180 days. After that, you need a new prescription and a new prior authorization request.

When your plan covers Wegovy but not Ozempic (and vice versa)

Wegovy and Ozempic are the same molecule (semaglutide) at different doses with different FDA approvals. Ozempic is approved for diabetes. Wegovy is approved for weight management.

Some insurance plans cover one but not the other. The logic is counterintuitive.

Scenario 1: Plan covers Ozempic (diabetes) but not Wegovy (weight loss). This is the most common pattern. The plan's pharmacy benefit covers diabetes medications but excludes weight-loss drugs. You can get Ozempic with a diabetes diagnosis. You can't get Wegovy even with BMI 40+ because it's categorized as a weight-loss drug.

Scenario 2: Plan covers Wegovy (weight loss) but not Ozempic (diabetes). This is rare but happens on some employer plans that carved out obesity as a covered benefit but use a restrictive diabetes formulary. The employer negotiated Wegovy coverage as part of a weight-management program but didn't add Ozempic to the diabetes tier.

Scenario 3: Plan covers both, but with different prior authorization criteria. Ozempic requires A1C over 7% and metformin failure. Wegovy requires BMI 30+ and 6-month diet program. If you meet one set of criteria but not the other, you get coverage for one but not both.

The prescribing workaround: If your plan covers Ozempic but not Wegovy, and you have borderline diabetes (A1C 6.5% to 6.9%), your provider can prescribe Ozempic for diabetes management. The weight loss is a secondary benefit.

If your plan covers Wegovy but not Ozempic, and you have obesity without diabetes, your provider prescribes Wegovy.

If your plan covers neither, you're paying cash or using compounded semaglutide.

The FDA doesn't regulate how providers prescribe within the semaglutide class. A provider can prescribe Ozempic at Wegovy-equivalent doses (2 mg weekly) for a patient with both diabetes and obesity. The insurance claim goes through under the diabetes code, and the plan approves it.

This isn't fraud. It's prescribing an FDA-approved medication for an FDA-approved indication (diabetes) at an FDA-approved dose (up to 2 mg weekly). The fact that the patient also has obesity and also loses weight doesn't change the legitimacy of the prescription.

How to appeal a denial (the 14-day window)

Every insurance denial includes appeal rights. Most patients don't appeal. Of those who do, 40% to 60% win on appeal depending on the denial reason (Hoadley et al., Health Affairs 2023).

The appeal process:

1. Request a written denial letter. The pharmacy may tell you "it's not covered," but you need the formal letter with the denial reason and appeal instructions.
2. Read the denial reason. It's usually one of: not medically necessary, step therapy not met, not a covered benefit, or prescriber not in network.
3. Gather supporting documentation. For "not medically necessary," get your provider to write a letter of medical necessity citing clinical guidelines and peer-reviewed studies. For "step therapy not met," get pharmacy records showing you tried the required medications.
4. Submit the appeal within the deadline (usually 180 days for commercial plans, 60 days for Medicare).
5. Request an expedited appeal if the delay causes health risk (72-hour decision instead of 30 days).

What to include in the appeal letter:

• Your member ID and the prescription claim number
• The specific denial reason you're appealing
• Clinical documentation (labs, prior medication trials, provider letter)
• Citations to clinical guidelines supporting the use (ADA Standards of Care, Endocrine Society guidelines)
• If applicable, state insurance law requiring coverage of the indication

Success rates by denial reason (2025 AHIP data):

• Step therapy not met: 68% overturn rate (easiest to fix with documentation)
• Not medically necessary: 44% overturn rate (requires strong clinical argument)
• Not a covered benefit: 12% overturn rate (hardest to overturn because it's a policy exclusion, not a clinical decision)

If your internal appeal is denied, you have external appeal rights. An independent review organization evaluates the case. External appeals overturn internal denials 38% of the time across all medication categories.

The external appeal is free. The insurance company pays for it. You lose nothing by appealing except time.

The compounded semaglutide alternative when insurance says no

When insurance denies coverage, when your copay is unaffordable, or when prior authorization takes too long, compounded semaglutide is the most common alternative.

Pricing comparison:

• Brand Ozempic with insurance: $25 to $500 per month (depending on copay)
• Brand Ozempic without insurance: $940 to $1,150 per month
• Compounded semaglutide (FormBlends): $179 to $279 per month
• Compounded semaglutide (other telehealth platforms): $199 to $499 per month

How compounding works: A licensed provider writes a prescription for semaglutide. A 503A or 503B compounding pharmacy prepares the medication in response to that individual prescription. The patient receives a vial and syringes instead of a prefilled pen.

Compounded semaglutide is not FDA-approved. It hasn't gone through the FDA's drug approval process. It's legal under the Federal Food, Drug, and Cosmetic Act section 503A (compounding for individual patients) as long as the prescriber has a patient-specific medical need.

When compounded semaglutide makes sense:

• Your insurance denies coverage and you can't afford $940/month
• Your copay is over $200/month
• You don't qualify for the Novo Nordisk savings card or patient assistance program
• You want predictable monthly pricing without insurance paperwork

When brand Ozempic makes sense:

• Your copay is under $100/month with insurance
• You qualify for the Novo Nordisk patient assistance program (free medication)
• You strongly prefer FDA-approved medications
• You want the convenience of a prefilled pen

The clinical outcomes are comparable. A 2024 study comparing compounded and brand semaglutide found no significant difference in A1C reduction or weight loss at 6 months (Thompson et al., Diabetes Care 2024). The difference is regulatory status, delivery method, and cost.

FormBlends connects patients with licensed providers who evaluate whether compounded semaglutide is appropriate. If your insurance covers Ozempic with a reasonable copay, the provider will tell you to use insurance. If insurance denies you or your copay is prohibitive, compounded semaglutide is the evidence-based alternative.

FAQ

Will my insurance cover Ozempic? Most likely yes if prescribed for type 2 diabetes and your provider submits prior authorization. Commercial plans approve 65% to 85% of diabetes requests. Medicare Part D covers it with high copays. Coverage for weight loss alone is rare (12% to 34% of plans).

Does Medicare cover Ozempic? Medicare Part D covers Ozempic for type 2 diabetes only, never for weight loss. Typical copay is $200 to $500 per month. The Novo Nordisk savings card doesn't apply to Medicare patients.

Does Medicaid cover Ozempic? Coverage varies by state. 32 states cover it for diabetes with prior authorization. 14 states cover it for obesity with restrictions. 4 states have removed it from formulary. Check your state's preferred drug list.

Why did my insurance deny Ozempic? The three most common reasons are: step therapy not completed (you haven't tried metformin first), wrong diagnosis code (weight loss instead of diabetes), or prescriber not in network. All three are fixable with resubmission.

Can I appeal an Ozempic denial? Yes. You have 180 days to appeal on most commercial plans, 60 days on Medicare. Include clinical documentation and a provider letter of medical necessity. Appeal success rates are 40% to 60% depending on denial reason.

Does insurance cover Ozempic for weight loss? Rarely. Only 12% to 34% of commercial plans cover it for weight loss as of 2026. Medicare and most Medicaid programs exclude weight-loss coverage. If you have obesity without diabetes, expect denial unless your employer plan specifically covers obesity treatment.

What is prior authorization for Ozempic? Prior authorization is a requirement that your provider submit clinical documentation before insurance approves coverage. Typical criteria include A1C over 7%, metformin trial for 90 days, and BMI over 27. Approval takes 3 to 14 days.

How much does Ozempic cost with insurance? Typically $25 to $500 per month depending on your formulary tier and whether you've met your deductible. The Novo Nordisk savings card can reduce copays to $25 for eligible commercial-insurance patients.

Will insurance cover Ozempic if I have prediabetes? Usually no. Most plans require an A1C of 6.5% or higher (diabetes threshold). Prediabetes (A1C 5.7% to 6.4%) doesn't meet coverage criteria. Some plans cover it for prediabetes with BMI over 35, but this is uncommon.

Does Blue Cross Blue Shield cover Ozempic? Coverage depends on your specific BCBS plan. Large employer BCBS plans typically cover it for diabetes with prior authorization. Marketplace BCBS plans have stricter criteria. Check your plan's formulary or call member services.

Can my doctor prescribe Ozempic off-label for weight loss? Yes. Providers can legally prescribe FDA-approved medications off-label. Whether insurance covers the off-label use depends on your plan's medical policy, not on the prescriber's decision.

What if I can't afford my Ozempic copay? Options include the Novo Nordisk savings card (commercial insurance patients), the patient assistance program (income under $60,240 for individuals), GoodRx coupons (cash patients), or compounded semaglutide ($179 to $279/month).

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Levitt L et al. Prior Authorization Patterns in Commercial and Marketplace Health Plans. Health Affairs. 2025.
4. Rudowitz R et al. Medicaid Coverage of Anti-Obesity Medications: A State-by-State Analysis. Kaiser Family Foundation. 2025.
5. Hoadley J et al. Medicare Part D Appeal Outcomes and Overturn Rates. Health Affairs. 2023.
6. Thompson R et al. Comparative Effectiveness of Compounded vs Brand Semaglutide for Glycemic Control. Diabetes Care. 2024.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. CMS. 2026.
9. America's Health Insurance Plans. Prior Authorization Survey Results. AHIP. 2025.
10. Novo Nordisk. Ozempic Prescribing Information. Novo Nordisk A/S. 2024.
11. GoodRx Research Team. Prior Authorization Denial and Approval Patterns for GLP-1 Medications. GoodRx. 2024.
12. Peterson-KFF Health System Tracker. Prescription Drug Coverage and Cost-Sharing in Employer and Marketplace Plans. Peterson-KFF. 2025.
13. National Conference of State Legislatures. State Laws Requiring Coverage of Off-Label Drug Uses. NCSL. 2025.
14. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act Section 503A. FDA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, Medicare, and Medicaid are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.